Mikael Kubista

TATAA Biocenter was the first laboratory in Europe to obtain flexible ISO 17025 accreditation and also was the first to provide COVID tests at the onset of the pandemic.

Mikael Kubista (born 13 August 1961) is Czech-born Swedish chemist and entrepreneur who works in the field of molecular diagnostics.

Kubista was born to his medical doctor father in the former Czechoslovakia in 1961.

His father received a scholarship and relocated to Sweden.

At the age of 7 in 1968, Kubista went to Sweden to visit his father.

However, on that very day, Russia invaded Czechoslovakia in the so called Warsaw Pact invasion of Czechoslovakia, and as a result, the family decided to stay making Sweden their new home.

He completed his undergraduate studies at University of Gothenburg, earning a B.Sc.

degree in chemistry in 1984.

He then pursued a Licentiate in Physical Chemistry at the Institute of Chemistry and Chemical Engineering, Chalmers University of Technology in Göteborg, which he completed in 1986.

Kubista obtained his Ph.D. in chemistry from Chalmers University of Technology.

Following his doctoral studies, he conducted postdoctoral research at institutions such as La Trobe University in Melbourne, Australia, and Yale University in New Haven, US.

Kubista began his academic career in 1991 as an Assistant Professor in the Department of Physical Chemistry at Chalmers University of Technology.

From 1993 to 1997, he served as an Associate Professor in the Department of Biochemistry at the same institution.

Following this, he held the position of Professor in the Department of Biochemistry at Chalmers University of Technology from 1997 to 2006.

In 1998 Kubista founded LightUp Technologies AB after his research finding of lightUp probes, a company that specializes in the development of real-time PCR tests for human infectious diseases.

Since 1999, he has served as an advisor to UNESCO, providing guidance and assistance to countries such as: Libya, Egypt, Iran, Grenada, and Ghana.

Kubista is an expert advisor for the European Commission Research Directorate General.

He also works as a special consultant in the Life Science field for AFRY and Pharma Relations.

Kubista advises the United Nations Educational Scientific and Cultural Organization (UNESCO) and is part of the scientific advisory board for the International Biotechnology Research in Tripoli, Libya, under UNESCO.

Additionally, he has held visiting professor positions at various universities, including the University of Maryland in College Park, US, in June 2000, and the University of A Coruña in Spain, during September–November 2003 and July 2006 to June 2007.

Three years later In 2001, Kubista's research led to the establishments of MultiD Analyses AB, which develops GenEx software for gene expression data analysis and TATAA Biocenter for qPCR and gene expression analysis.

The company became known for its qPCR training services globally and its provision of qPCR services, particularly in Europe.

Since 2007, he is serving as a Professor of Chemistry and Head of the Department of Gene Expression Profiling at the Biotechnology Institute, Czech Academy of Sciences in the Czech Republic.

Kubista has contributed to the field of quantitative real-time PCR (qPCR), with his work recognized as part of the early research in this area.

Kubista was a member of the research team at Astra Hässle, where they focused on investigating Omeprazole, an inhibitor of K+/H+-ATPase.

The drug is now marketed under the trade names Losec and Nexium, widely prescribed medications for the treatment of gastric ulcer.

Additionally, Kubista is the Chairman of the Board of MultiD Analyses AB and the founder of TATAA Biocenter.

Since 2007, Kubista is serving as an adjunct professor at the Institute of Biotechnology, Czech Academy of Sciences.

Since 2007, he is the Head of the Department of Gene Expression at the Institute of Biotechnology, BIOCEV, Czech Academy of Sciences.

In 2014 Kubista implementated non-invasive prenatal testing (NIPT) in Sweden and subsequently founded Life Genomics AB.

In 2020, Kubista co-founded SimSen Diagnostics, a company focused on developing technology for liquid biopsy analyses.

Kubista holds several positions and advisory roles within the scientific and biotechnology communities including: Roche, ThermoFisher, Qiagen, Bio-Rad, and RealSeq Biosciences.

He is also a member of the Scientific Advisory Council of Genetic Engineering News.

Kubista has also been involved in the establishment of modern molecular diagnostics in developing countries.